RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has scheduled a webcast for Wednesday, June 9 at 4:00 PM Eastern Time. At that time, management will review the results from the recently completed Phase 1B clinical study to reverse low molecular weight heparin with PMX-60056.
